Modifying One Position on THC Created Compounds That Preferentially Targeted the CB2 Immune Receptor
Researchers identified a specific molecular position (C-1) on classical cannabinoids where modifications produced compounds with selectivity for the CB2 receptor, potentially separating therapeutic effects from psychoactive ones.
Quick Facts
What This Study Found
Separating the mood-altering effects of cannabinoids from their therapeutic effects has been a long-standing goal. This study found that modifications at the C-1 position of classical cannabinoid structures produced compounds with selectivity for the CB2 receptor over the CB1 receptor.
A series of cyclic ether THC derivatives were synthesized and tested. Analogs containing an oxygen attached to C-9 showed the highest CB2 affinity and selectivity, with one compound achieving a CB2 binding affinity of 5.8 nM and a selectivity ratio of 4.5.
The compounds produced dose-dependent effects in tissue assays that were blocked by a CB1 antagonist. In live animals, one analog produced pain relief with reduced activity in three other behavioral measures, suggesting partial separation of therapeutic and psychoactive effects.
Key Numbers
Best CB2 compound: Ki(CB1) = 26 nM, Ki(CB2) = 5.8 nM, selectivity ratio 4.5. Another compound: Ki(CB1) = 90 nM, Ki(CB2) = 23 nM, selectivity ratio 3.9.
How They Did This
Medicinal chemistry study synthesizing five C-9 analogs of O,2-propano-delta-8-THC. Compounds were evaluated using radioligand displacement assays for CB1 and CB2 receptor affinity, mouse vas deferens tissue assays, and the mouse behavioral tetrad for in vivo cannabinoid activity.
Why This Research Matters
This study identified a specific molecular position for achieving CB2 receptor selectivity, which is important because CB2 activation may produce anti-inflammatory and pain-relieving effects without the psychoactive effects mediated by CB1. This work advanced the goal of creating therapeutic cannabinoids without the "high."
The Bigger Picture
CB2-selective cannabinoids remain an active area of pharmaceutical development. The identification of the C-1 position as key for selectivity contributed to the rational design of subsequent CB2-selective compounds for potential treatment of inflammation, pain, and other conditions without psychoactive effects.
What This Study Doesn't Tell Us
The selectivity ratios achieved (3.9-4.5) were modest. Mouse behavioral assays may not predict human pharmacology. Only a small series of analogs was tested.
Questions This Raises
- ?Can greater CB2 selectivity be achieved with further modifications?
- ?Do CB2-selective compounds produce meaningful therapeutic effects in humans?
- ?Has this C-1 position insight led to clinical development of CB2-selective drugs?
Trust & Context
- Key Stat:
- CB2 selectivity ratio of 4.5 achieved through C-1 position modification
- Evidence Grade:
- A medicinal chemistry study with in vitro binding assays and in vivo behavioral testing. Rigorous pharmacology but early-stage drug discovery.
- Study Age:
- Published in 1997. CB2-selective drug development has continued, with several compounds reaching clinical trials for various conditions.
- Original Title:
- Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
- Published In:
- Journal of medicinal chemistry, 40(20), 3312-8 (1997)
- Authors:
- Reggio, P H(3), Wang, T, Brown, A E, Fleming, D N, Seltzman, H H, Griffin, G, Pertwee, R G, Compton, D R, Abood, M E, Martin, B R
- Database ID:
- RTHC-00061
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is the CB2 receptor?
CB2 is a cannabinoid receptor found primarily in immune cells and peripheral tissues. Unlike CB1 (found in the brain), CB2 activation is not thought to produce psychoactive effects.
Could this lead to non-psychoactive cannabis medicines?
That is the goal. By targeting CB2 selectively, researchers hope to create cannabinoid drugs that provide therapeutic benefits without the mind-altering effects of THC.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00061APA
Reggio, P H; Wang, T; Brown, A E; Fleming, D N; Seltzman, H H; Griffin, G; Pertwee, R G; Compton, D R; Abood, M E; Martin, B R. (1997). Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.. Journal of medicinal chemistry, 40(20), 3312-8.
MLA
Reggio, P H, et al. "Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.." Journal of medicinal chemistry, 1997.
RethinkTHC
RethinkTHC Research Database. "Importance of the C-1 substituent in classical cannabinoids ..." RTHC-00061. Retrieved from https://rethinkthc.com/research/reggio-1997-importance-of-the-c1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.